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Abstract: Patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
have a poor overall prognosis despite chemotherapy and radiotherapy (e.g., peptide receptor ra-
dionuclide therapy (PRRT)). Better treatment options are needed to improve disease regression and
patient survival. The purpose of this study was to examine a new treatment strategy by combining
PI3K/mTOR dual inhibition and radiotherapy. First, we assessed the efficacy of two PI3K/mTOR
dual inhibitors, PF-04691502 and PKI-402, to inhibit pAkt and increase apoptosis in NET cell lines
(BON and QGP-1) and patient-derived tumor spheroids as single agents or combined with radio-
therapy (XRT). Treatment with PF-04691502 decreased pAkt (Ser473) expression for up to 72 h
compared with the control; in contrast, decreased pAkt expression was noted for less than 24 h with
PKI-402. Simultaneous treatment with PF-04691502 and XRT did not induce apoptosis in NET cells;
however, the addition of PF-04691502 48 h after XRT significantly increased apoptosis compared to
PF-04691502 or XRT treatment alone. Our results demonstrate that schedule-dependent adminis-
tration of a PI3K/mTOR inhibitor, combined with XRT, can enhance cytotoxicity by promoting the
radiosensitivity of NET cells. Moreover, our findings suggest that radiotherapy, in combination with
timed PI3K/mTOR inhibition, may be a promising therapeutic regimen for patients with GEP-NET.
Keywords: neuroendocrine tumor; radiosensitization; PI3K inhibitor
1. Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous clinical
and pathological subsets of NETs arising from the gastrointestinal tract. Historically,
NETs have been considered an “orphan” disease [1]. However, the incidence of these
tumors increased approximately 6.4-fold from 1973 to 2012, which is likely attributed
to advanced imaging and earlier diagnosis [2]. Among all NETs, GEP-NETs have the
highest incidence, at 3.56 per 100,000 population [2]. In addition, many patients experience
diagnostic delays due to the lack of specific presenting symptoms. In contrast to these early-
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stage asymptomatic patients, symptomatic patients are often diagnosed with advanced or
metastatic disease and have a poor overall prognosis [3].
Peptide receptor radionuclide therapy (PRRT) has emerged as an effective therapeutic
modality for treating GEP-NETs, with clinical trials showing increased progression-free
survival and overall survival in patients [4–8]. Somatostatin receptors are highly expressed
in 80–100% of GEP-NETs [9,10]. Synthetic somatostatin analogues, which have a high
affinity to GEP-NETs, and coupled with a radioactive element, facilitate uptake into cells
to deliver targeted intracellular radiation [7,9]. The PRRT compounds currently available
in the United States and approved for treatment of GEP-NETs include 177Lu-Octreotide,
90Y-DOTATOC, and 111In-DTPA-octreotide [9]. 177Lu-Octreotide has achieved partial and
minor response rates of 29% and 16%, respectively, and improved progression-free survival
and overall survival in the NETTER-1 phase III clinical trial, thus indicating the utility of
PRRT as a potential treatment option for inoperable or metastatic disease [8,9]. Another
evolving approach in cancer treatment is to utilize a multimodal regimen to enhance the
effects of single agents for tumor regression. For example, radiosensitizers, such as 5-FU,
capecitabine, and temozolomide, have been tested in conjunction with PRRT [11–13].
The mammalian target of rapamycin (mTOR) and the PI3K/mTOR/Akt signaling
pathway play a role in tumor proliferation, survival and angiogenesis [14]. Treatment with
everolimus, a potent inhibitor of the mTORC1 subunit, significantly improved progression-
free survival in the RAD001 in advanced neuroendocrine tumors (RADIANT) clinical
trials [15–20]. Of particular interest, mTOR inhibitors have been tested in vitro as ra-
diosensitizers in combination with PRRT [21]. Recently, PRRT combination therapy with
everolimus has entered phase I/II clinical trials [22,23]. Although this combination therapy
has demonstrated an improved treatment response rate of 44%, serious side effects, such
as neutropenia and renal function impairment, occurred in 8 out of 11 patients in one
study, requiring dose reduction [22,23]. New combination strategies may improve patient
tolerance to PI3K/mTOR, such as inhibiting PI3K/mTOR pathway only when cancer
cells experience radiation-induced stress, which may offer short-term synergistic effects
combined with radiotherapy.
Novel and promising PI3K and mTOR dual inhibitors with advanced antineoplastic
properties, such as PF-04691502 and PKI-402, inhibit multiple targets in the PI3K/mTOR/
Akt pathway and may be superior therapeutic agents compared to everolimus [24]. PI3K/
mTOR dual inhibitors have been assessed in several clinical trials as a treatment for various
advanced cancers, but rarely GEP-NET [25–28]. Furthermore, little is known about the
effect of PI3K/mTOR inhibition and radiosensitization of GEP-NET cells. In this study,
we evaluated the response of GEP-NET cells to the combination of a novel PI3K/mTOR
inhibitor in conjunction with radiotherapy. Our results show that schedule-dependent
administration of a dual PI3K/mTOR inhibitor and radiotherapy can improve treatment
response by increasing apoptosis in vitro. Furthermore, our results suggest that this
combination strategy may be a potential treatment to improve disease regression and
progression-free survival among GEP-NET patients.
2. Materials and Methods
2.1. Materials and Reagents
Tissue plates were from Olympus (Olympus Cooperation, Tokyo, Japan): 6-well
flat bottom tissue culture plate (25–105), 96-well flat bottom tissue culture plate (25–109);
Corning (Corning Inc, New York, NY, USA): 24-well low attachment plates (CLS3473),
96-well clear round bottom ultra-low attachment microplate (7007) and Millipore Sigma
(MilliporeSigma, Burlington, MA, USA): collagen IV-coated plates (collagen from human
placenta; C7521). A sterile cell strainer 70 µm nylon mesh was from FisherBrand (Fisher Sci-
entific, Hampton, NH, USA; 22-363-548). The cell culture medium and reagents included:
Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco Thermo Fisher Scientific,
Waltham, MA; 11875085), DMEM/F12-GlutaMAXTM medium (Gibco Thermo Fisher Scien-
tific, Waltham, MA, USA; 10565018), HyClone™ HEPES (GE Healthcare, Chicago, IL, USA;
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SH30237.01), IntestiCult organoid growth medium (Stemcell Technologies, Vancouver,
Canada; 06010), recombinant human FGF-basic (Peprotech, Rocky Hill, NJ, USA; 100-18B),
epidermal growth factor (BioVision, Milpitas, CA, USA; 4022), non-essential amino acid
solution (Millipore Sigma, Burlington, MA, USA; M7145), sodium pyruvate solution (Mil-
lipore Sigma, Burlington, MA, USA; S8636), MEM vitamin solution (Millipore Sigma,
Burlington, MA, USA; M6895), Liberase DH (Roche Applied Science, Penzberg, Germany;
05401054001), collagenase/hyaluronidase (StemCell Technologies, Vancouver, Canada;
07912), trypsin-EDTA solution (Sigma-Aldrich, St. Louis, MO, USA; SLCB7154), antibiotic-
antimycotic 100 X (Gibco Thermo Fisher Scientific, Waltham, MA, USA; 15240-062), fetal
bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA; 12303C-500), Accumax (Innova-
tive Cell Technologies, San Diego, CA, USA; AM105).
PI3K/mTOR dual inhibitors used in this study were PF-04691502 (Selleckchem, Hous-
ton, TX, USA; S2743) and PKI-402 (Selleckchem, Houston, TX, USA; S2739). Drugs were
diluted in dimethyl sulfoxide (DMSO) (Fisher Scientific, Waltham, MA, USA; D128-500)
and stored at −80 ◦C prior to use. A cell medium mixture with DMSO only was added to
cells in the control group.
Western blot materials included: Dulbecco’s phosphate buffered saline (PBS) (Sigma-
Aldrich, St, Louis, MO, USA; D8637-500), RIPA buffer 10X (Cell Signaling Technology,
Danvers, MA, USA; 9806S), protein assay dye (Bio-Rad Laboratories, Hercules, CA, USA;
5000006), MOPS SDS running buffer 20 X (Invitrogen, Carlsbad, CA, USA; NP0001-02),
Tris-Glycine 10 X transfer buffer solution (Fisher Scientific, Waltham, MA, USA; BP1306-1),
TBS buffer 20 X (VWR International, Radnor, PA, USA; J640-4L), Tween 20 (Fisher Scien-
tific, Waltham, MA, USA; BP337-500), NuPAGETM 4–12% Bis-Tris Gel 1.0 mm × 10 well
(Invitrogen, Carlsbad, CA, USA; NP0321B0X), NuPAGETM LDS sample buffer 4 X (Invitro-
gen, Carlsbad, CA, USA; NP0007), NuPAGETM sample reducing agent (Novex Products
Inc, Lorain, OH, USA; NP0009), phenylmethanesulfonyl fluoride (PMSF) solution 100 X
(Sigma-Aldrich, St. Louis, MO, USA; 93482-50), Precision Plus ProteinTM dual color stan-
dards (Bio-Rad Laboratories, Hercules, CA, USA; 161-0374), sodium azide (Fisher Scientific,
Waltham, MA, USA; S2271-100), non-fat dry milk (Lab Scientific, Danvers, MA, USA;
M0841), methanol (VWR International, Radnor, PA, USA; BDH1135-4LP), Amersham ECL
prime Western blotting detection reagent (GE Healthcare Life Sciences, Chicago, IL, USA;
RPN2209), and Immobolin Western (Millipore Sigma, Burlington, MA, USA; WBKLS0500).
The following primary antibodies were from 1) Abcam (Cambridge, United Kingdom):
anti-chromogranin A (ab45179, 1:500), recombinant anti-cyclin D1 antibody (ab134175,
1:5000); 2) Santa Cruz Biotechnology Inc (Dallas, TX, USA): SSTR2 antibody (A-8) (SC-
365502, 1:100), SYP antibody (4H255) (SC-58301, 1:100); and 3) Cell Signaling Technology
(Danvers, MA, USA): phospho-Akt (Ser473) (D9E) XP ® rabbit mAb (4060, 1:1000), Akt
(pan) (40D4) mouse mAb (2920, 1:1000), S6 ribosomal protein (5G10) rabbit mAb (2217,
1:1000), 4E-BP1 (53H11) rabbit mAb (9644, 1:1000), phospho-4E-BP1 (Thr37/46) (236B4)
rabbit mAb (2855, 1:1000), phospho-S6 ribosomal protein (Ser235/236) (D57.2.2E) XP ®
rabbit mAb (4858, 1:2000), cleaved PARP (Asp 214) (D64E10) XP® rabbit mAb (5625, 1:1000),
PARP (46D11) rabbit mAb (9532, 1:1000), β-Actin (8H10D10) mouse mAb (3700, 1:5000)
and GAPDH (14C10) rabbit mAb (2118, 1:1000). Secondary antibodies were from Santa
Cruz Biotechnology (Dallas, TX, USA): mouse anti-rabbit IgG-HRP (SC-2357), and m-IgGk
BP-HRP (SC-516102).
Proliferation and colorimetric cell survival analyses were performed with CytoScanTM
SRB Cell Cytotoxicity Assay (G-Biosciences, Geno Technology Inc, St. Louis, MO, USA;
786-213) [29].
CCK-8 viability analysis was performed with CCK-8 reagent (MedChemExpress LLC,
Monmouth Junction, NJ, USA; HY-K0301).
A DNA fragmentation ELISA photometric enzyme immunoassay was performed with
the Cell Death Detection ELISAPLUS kit (Roche Holding AG, Basel, Switzerland; C755B93).
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Cell count and viability were determined by the Vi-Cell BLU cell viability analyzer
(Beckman Coulter Life Sciences, Brea, USA). Photospectrometry was conducted by the
Varioskan LUX microplate reader (ThermoFisher Scientific, Waltham, MA, USA).
2.2. Cell Culture
The BON cell line was derived from a human pancreatic neuroendocrine tumor and
previously characterized [30,31]. QGP-1, a pancreatic neuroendocrine cell line purchased
from Japan Health Sciences Foundation [32], was maintained in ATCC-formulated RPMI
1640 medium with 10% fetal bovine serum and 1% 100 × penicillin antibody solution. The
NT-3 cells, derived from a human pancreatic NET, were a kind gift from Dr. Jörg Schrader
(University Medical Center Hamburg-Eppendorf, Hamburg, Germany). All cells were
cultured in a humidified incubator at 37 ◦C and 5% CO2. QGP-1 cells were cultured in
RPMI-1640 + 10% FBS + 1% 100 × penicillin antibody solution. BON cells were cultured
in a 1:1 mixture of DMEM F1/2 GlutaMAX supplemented with 10% fetal bovine serum
and 1% 100 × penicillin antibody solution in 5% CO2 at 37 ◦C. NT-3 cells were cultured
in RPMI medium supplemented with 10% FBS, 10 mM HyClone™ HEPES, 1X antibiotic-
antimycotic, 20 ng/mL epidermal growth factor, 10 ng/mL recombinant human FGF-basic.
NT-3 cells were cultured on collagen IV-coated plates. Collagen IV solution was prepared
in PBS for coating cell culture plates at 50 µg/mL concentration [33].
2.3. NET Tumor Spheroids
Patient samples were collected under Markey Cancer Center Tissue Collection for
Tumor Research protocol (IRB #44231). The original patient NET tumor (F0 generation)
was divided into 2 mm3 pieces and digested in 50 µg/mL Liberase DH (100 µL) and 0.5 X
collagenase/hyaluronidase (250 µL), diluted in 5 mL of DMEM/F12 serum free media for
4 h at 37 ◦C with gentle agitation by a magnetic stirring bar. Liberase DH was resuspended
in sterile water (2.5 mg/mL concentration) and stored in single-use 100 µL aliquots at
−80 ◦C. Collagenase/hyaluronidase was aliquoted into single-use 250 µL aliquots and
stored at −80 ◦C. Digested cells were washed twice with complete cell culture media
and transferred into 24-well low-attachment plates in 10% DMEM/F12 FBS, 1 X MEM
non-essential amino acid solution, 10 mM sodium pyruvate solution, 1 X MEM vitamin
solution, 10 mM HyClone™ HEPES. Cell culture media were supplemented with 1 X
antibiotic-antimycotic, 20 ng/mL epidermal growth factor, 10 ng/mL recombinant human
FGF-basic. IntestiCult organoid growth medium was added to each well of the 24-well
plates in a 1 to 4 proportion to culture media.
2.4. Radiotherapy
Cells were irradiated using a Precision X-Ray irradiator (X-RAD-225XL, North Bran-
ford, CT, USA) at the X-ray Service Center of the Department of Toxicology and Cancer
Biology of the University of Kentucky (Ref: 32438621 and 30673636). The energy of
the X-ray used was 225 kV at a dose rate of approximately 1.7 Gy/min. Accurate ab-
sorbed doses were calculated by considering the impact of backscattering as previously
described [34]. To determine radiation dose-dependent apoptosis, cells were irradiated (2,
4, and 8 Gy) once, followed by incubation for 48, 72, and 96 h. To assess the synergistic
effect of radiotherapy and PF-04691502, cells were irradiated (2 Gy) once, incubated for 48,
72, and 96 h, followed by PF-04691502 treatment (500 or 1000 nM) for 24 h. To determine
DNA fragmentation, a marker for induced cell death and apoptosis, cells were irradiated
(2 Gy), incubated for 96 h, followed by 500 nM PF-04691502 treatment for 24 h. Finally, to
determine the synergistic effect of simultaneous radiotherapy and PF-04691502, cells were
irradiated (2 and 4 Gy) and immediately treated with PF-04691502 (500 nM or 1000 nM),
followed by incubation for 24 h.
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2.5. Immunohistochemistry
GEP-NET patient tissue samples (n = 39) were identified by the Markey Cancer
Center Biospecimen Procurement and Translational Pathology Shared Resource Facility.
Immunohistochemistry (IHC) was performed as previously described [35]. Briefly, slides
were deparaffinized in xylene, rehydrated, incubated for 15 min with fresh 0.3% hydrogen
peroxide, washed with PBS, and heated to 95 ◦C for 30 min in sodium citrate buffer (10 mM
sodium citrate, 0.05% Tween 20, pH 6.0).
Endogenous peroxidase activity was blocked with Bloxall blocking solution (Vector
Laboratories, Burlingame, CA, USA; SP-6000). Next, sections were blocked for 1 h with
2.5% normal horse serum (Vector Laboratories, Burlingame, CA, USA; S-2012). pAkt
(Ser473) antibody was diluted in Dako background reducing antibody diluent (Agilent
Dako Products, Santa Clara, CA, USA; S3022). Primary antibody was incubated with
slides for 12 h at 4 ◦C in a humidifier chamber, washed with Tris-buffered saline and
Tween 20 (TBST) and incubated with ImmPRESS universal antibody IgG polymer detection
kit (Vector Laboratories, Burlingame, CA, USA; MP-7500) for 1 h at room temperature.
Antibody reaction was visualized with Immpact DAB EqV peroxidase substrate (Vector
Laboratories, Burlingame, CA, USA; SK-4103). All sections were counterstained with
hematoxylin (VWR international, Radnor, PA, USA; 95057-844) and observed by light
microscopy. For negative controls, primary antibody was omitted from the above protocol.
The number of positive cells was visually evaluated in each core by a pathologist, and
the staining intensity was classified using a semi-quantitative seven-tier system developed
by Allred et al. [36,37]. The system assesses the percentage of positive cells (none = 0;
<10% = 1; 10% to 50%, = 2; >50% = 3) and intensity of staining (none = 0; weak = 1;
intermediate = 2; and strong = 3).
2.6. Immunoblotting
Cells were seeded at 800,000/2 mL in 6-well plates. To determine inhibition of the
mTOR/pAkt pathway, cells were treated with either PKI-402 (50 to 1000 nM) or PF-04691502
(100 to 10000 nM) for 24, 48, and 72 h and selected tumor spheroids were treated with
PF-04691502 (500 nM) for 24 h prior to lysis. To examine markers for NET origin, the
selected tumor spheroids were incubated in a humidified 37 ◦C 5% CO2 incubator for
7 d prior to lysis. To determine the synergistic effect on apoptosis, cells were treated by
means of radiotherapy or radiotherapy combined with PF-04691502 as described above,
prior to lysis. The immunoblotting for individual experiments was performed as previously
described [38].
2.7. Sulforhodamine B (SRB) proliferation assay
Cells were seeded at 5000 cells/100 µL in 96-well plates and treated with PF-04691502
(100 nM to 10,000 nM), followed by incubation in a humidified 37 ◦C 5% CO2 incuba-
tor. Cells were then fixed, stained, and quantified following the CytoscanTM SRB Cell
Cytotoxicity Assay protocol [29].
2.8. Colorimetric cell survival assay
Cells were seeded at 500 cells/100 µL in 96-well plates and treated with PF-04691502
(25 nM to 500 nM), followed by incubation in a humidified 37 ◦C 5% CO2 incubator for
14 d. Cells were then fixed and stained followed by quantification per Cytoscan SRB cell
cytotoxicity assay protocol [29].
2.9. CCK-8 Viability Assay
Tumor spheroids were established as described and cultured in 24-well ultra-low
attachment plates. First, tumor spheroids were collected into 50 mL conical tubes and cen-
trifuged at 2000 rpm; cell medium was removed, and tumor spheroids were resuspended
in Accumax solution for 15 min at 37 ◦C. Tumor spheroids were gently and thoroughly
pipetted with a 1 mL pipette to form a homogenous single cell suspension. Accumax solu-
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tion was then neutralized with complete cell medium. The cell suspension was centrifuged
at 2000 rpm, the supernatant was removed entirely, and the cells were resuspended in
complete medium. Cells were passed through a sterile cell strainer 70 µm nylon mesh to
remove any undigested tumor spheroids. Cells were seeded at 10,000 cells/100 µL density
per well into a 96-well clear round bottom ultra-low attachment microplate to allow the
formation of spheroids over the next 24 h. Finally, tumor spheroids were treated with
1000 nM PF-04691502 for 48 h, followed by the addition of CCK-8 reagent (20 µL), and
incubated for 72 h prior to analysis. Colorimetric change induced by CCK-8 reagent, which
is directly proportional to the rate of cell proliferation, was measured by absorbance at
450 nm.
2.10. DNA Fragmentation ELISA Photometric Enzyme Immunoassay
Cells were seeded at a 1000 cells/100 µL density in 96-well plates and treated by
radiotherapy alone or radiotherapy combined with PF-04691502 as described above prior
to quantification, as per the ROCHE Cell Death Detection ELISAPLUS protocol [39].
2.11. Statistical Analysis
Descriptive statistics, including means and SD, are presented in each experimen-
tal group and displayed in bar graphs. Percentage inhibition was calculated compared
to the control of each experiment and plotted against concentrations in a logarithmic
scale. The standard curves and absolute maximal inhibitory concentration (IC-50) values
were generated using SigmaPlot software version 14 (Systat Software Inc., San Jose, CA,
USA). Immunohistochemistry scores were summarized descriptively. Comparisons of SRB
absorbance, proliferation, colorimetric survival assay, CCK-8 viability assay, and DNA
fragmentation ELISA enzyme immunoassay were performed using one and two-way anal-
ysis of variance (ANOVA) with Holm’s adjustment for multiple testing between groups.
p < 0.05 was considered to indicate a statistically significant difference. Statistical analyses
were performed using SAS software version 9.4 (SAS Inc., Cary, NC, USA).
3. Results
3.1. PAkt (Ser473) Expression in GEP-NET Tumors
The PI3K/Akt/mTOR pathway has been implicated in GEP-NET development and
the improvement of progression-free survival [40,41]. pAkt expression was analyzed in
39 GEP-NET tumor samples; 88% of the samples were stained as strongly positive (score 5 or
6). The staining intensity was weak in 2% (score 3 or less) and intermediate in 10% of cases
(score 4) (Figure 1A,B and Figure S1). Positive cytoplasmic staining was observed in all
patient samples with positive pAkt staining. Although the sample number was somewhat
limited, these results suggest increased Akt activation in the majority of GEP-NETs.




Figure 1. Analysis of pAkt (Ser473) expression in NET patient samples. (A) Representative pAkt 
(Ser473) immunohistochemistry staining of patient neuroendocrine tumor samples. Positive stain-
ing was observed in the cytoplasm. Patient GEP-NET samples’ (n = 39) scores were evaluated by a 
pathologist and the staining intensity was classified using a semi-quantitative seven-tier system. 
(B) Percentage distributions of the cytoplasmic expression of pAkt (Ser473) scored by abundance 
and intensity is shown in the pie chart. 
3.2. Cellular Profiling of PI3K/mTOR Inhibitors, PF-04691502 and PKI-402, in GEP-NET 
Cancer Cell Lines 
To determine the activity of the novel PI3K/mTOR inhibitors on NETs, three well-
established human GEP-NET cell lines (QGP-1, BON, and NT-3) were treated with vari-
ous concentrations (50–1000 nM) of either PKI-402 or PF-04691502 over a defined time 
period. PKI-402 (500 and 10,000 nM) completely inhibited pAkt expression at 4 h in both 
QGP and BON cells (Figure S2). However, this effect was not prolonged, as noted by the 
attenuation of pAkt expression at 24 h with only the highest concentration (i.e., 1000 nM 
in QGP-1 cells and 500 nM in BON cells) (Figure 2A). In contrast, PF-04691502 potently 
inhibited pAkt expression in both QGP-1 (at concentrations of 100 to 10,000 nM) and BON 
(at concentrations of 100 to 10,000 nM) cell lines at 24 h after treatment (Figure 2B). Though 
both PKI-402 and PF-04691502 are ATP-competitive, reversible and specific PI3K/mTOR 
dual inhibitors, they differ in their pharmacokinetics [24,42]. For instance, PKI-402 partic-
ularly suppresses pAkt at Thr308 and requires a higher dose to inhibit pAkt at Ser428 [42]. 
Since complete activation of Akt kinases occurs when the mTORC2 complex phosphory-
lates Akt at Ser428, our study utilized Akt inhibition at Ser428 as the marker for Akt inhi-
bition [42]. 
Next, we treated QGP-1 and BON cells with PF-04691502 (500 nM) to test the dura-
tion of PI3K pathway inhibition (Figure 2C). The expression of pAkt was inhibited in both 
QGP-1 and BON cells at 24, 48 and 72 h. Similarly, expression of pS6 (Ser235/236), which 
is a key regulator of 40 S ribosome subunit biogenesis, was inhibited in both cell lines. 
Finally, we assessed the expression of p4EBP-1 (Thr37/46), which plays a critical role in 
translational mRNA complex assembly and found that PF-04691502 (500 nM) inhibited 
expression of this protein at all time points; p4EBP-1 expression was markedly attenuated 
at 24 and 48 h and completely inhibited at 72 h. A single treatment with PF-04691502 not 
only demonstrated sustained inhibition for the 24 h period in QGP-1 and BON cells (Fig-
ure 2B), but also attenuated pAkt, pS6 and p4EBP-1 at 24 h in NT-3 cells (data not shown). 
Moreover, these results demonstrate that PF-04691502 can effectively inhibit PI3K/mTOR 
pathway components in both QGP-1 and BON cells for at least 72 h. 
Figure 1. Analysis of pAkt (Ser473) xpression in NET patient samples. (A) Representative pAkt
(Ser473) immunohistochemistry staining of patient neuroendocrine tumor samples. Positive staining
was observed in the cytoplas . Patient GEP-NET samples’ ( = 39) scores were evaluated by a
pathologist and the staining intensity was classified using a semi-quantitative seven-tier system.
(B) Percentage distributions of the cytoplasmic expression of pAkt (Ser473) scored by abundance and
intensity is shown in the pie chart.
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3.2. Cellular Profiling of PI3K/mTOR Inhibitors, PF-04691502 and PKI-402, in GEP-NET Cancer
Cell Lines
To determine the activity of the novel PI3K/mTOR inhibitors on NETs, three well-
established human GEP-NET cell lines (QGP-1, BON, and NT-3) were treated with various
concentrations (50–1000 nM) of either PKI-402 or PF-04691502 over a defined time period.
PKI-402 (500 and 10,000 nM) completely inhibited pAkt expression at 4 h in both QGP and
BON cells (Figure S2). However, this effect was not prolonged, as noted by the attenuation
of pAkt expression at 24 h with only the highest concentration (i.e., 1000 nM in QGP-1 cells
and 500 nM in BON cells) (Figure 2A). In contrast, PF-04691502 potently inhibited pAkt ex-
pression in both QGP-1 (at concentrations of 100 to 10,000 nM) and BON (at concentrations
of 100 to 10,000 nM) cell lines at 24 h after treatment (Figure 2B). Though both PKI-402
and PF-04691502 are ATP-competitive, reversible and specific PI3K/mTOR dual inhibitors,
they differ in their pharmacokinetics [24,42]. For instance, PKI-402 particularly suppresses
pAkt at Thr308 and requires a higher dose to inhibit pAkt at Ser428 [42]. Since complete
activation of Akt kinases occurs when the mTORC2 complex phosphorylates Akt at Ser428,
our study utilized Akt inhibition at Ser428 as the marker for Akt inhibition [42].




Figure 2. pAkt (Ser473) inhibition by PKI-402 and PF-04691502 in NET cell lines. (A) QGP-1 and 
BON cells were seeded in a 6-well plate at 800,000 cells/2 mL density and treated with PKI-402 
from 50 to 1000 nM, and collected at 24 h. Western blot analysis was performed to confirm 
PI3K/Akt pathway inhibition at 24 h. (B) QGP-1 and BON cells were seeded in 6-well plates at 
800,000 cells/2 mL density and treated with PF-04691502 from 100 to 10,000 nM, and collected at 24 
h. Western blot analysis was performed to confirm PI3K/Akt pathway inhibition. (C) QGP-1 and 
BON cells were seeded in 6-well plates at 800,000 cells/2 mL density and treated with 500 nM PF-
04691502. Protein was collected at 24, 48, and 72 h. In addition to pAkt (Ser473) inhibition, down-
stream targets of the PI3K/Akt pathway, pS6 (Ser235/236) and p4EBP-1 (Thr37/46) inhibition, were 
confirmed with Western blot analysis. β-actin was used as a loading control. 
To determine the effect of PF-04691502 on GEP-NET cell proliferation, we treated 
QGP-1 and BON cells with concentrations ranging from 100 to 10,000 nM for 120 h. The 
percentage of cell inhibition was plotted against the concentration of PF-04691502 on a 
logarithmic scale, and a standard curve was fitted to calculate the absolute IC-50 values. 
A dose-dependent increase in percentage inhibition of cellular proliferation was observed 
in both QGP-1 and BON cells (Figure 3A,B). The absolute IC-50 value, defined as 50% 
inhibition compared to control, ranges from 168 nM for QGP-1 cells to 127.8 nM for BON 
cells. 
Next, we evaluated the effect of PF-04691502 on QGP-1 and BON cell survival. Cells 
were treated with PF-04691502 (from 25 to 500 nM) and cell survival was quantified as 
previously described. We noted a statistically significant decrease in cell survival at dos-
ages of 250 and 500 nM for both QGP-1 and BON cells (Figure 3C). These results demon-
strate significant antiproliferative activity of PF-04691502 in GEP-NET cell lines, particu-
larly at a dosage of 500 nM. 
Figure 2. pAkt (Ser473) inhibition by PKI-402 and PF-04691502 in NET cell lines. (A) QGP-1 and BON
cells were seeded in a 6-well plate at 800,000 cells/2 mL density and treated with PKI-402 from 50 to
1000 nM, and collected at 24 Western blot analysi as p rformed to confirm PI3K/Akt pathway
inhibition at 24 h. (B) QGP-1 and BON cells were seeded in 6-well plates at 800,000 cells/2 mL
density and treated with PF-04691502 from 100 to 10,000 nM, and collected at 24 h. Western blot
analysis was performed to confirm PI3K/Akt pathway inhibition. (C) QGP-1 a d BON cells were
seeded in 6-well plates at 800,000 cells/2 mL density and treated with 500 nM PF-04691502. Protein
was collected at 24, 48, and 72 h. In addition to pAkt (Ser473) inhibition, downstream targets of
the PI3K/Akt pathway, pS6 (Ser235/236) and p4EBP-1 (Thr37/46) inhibition, were confirmed with
Wester blot analysis. β-a tin was used as a loading contr l.
Cells 2021, 10, 1261 8 of 17
Next, we treated QGP-1 and BON cells with PF-04691502 (500 nM) to test the duration
of PI3K pathway inhibition (Figure 2C). The expression of pAkt was inhibited in both
QGP-1 and BON cells at 24, 48 and 72 h. Similarly, expression of pS6 (Ser235/236), which
is a key regulator of 40 S ribosome subunit biogenesis, was inhibited in both cell lines.
Finally, we assessed the expression of p4EBP-1 (Thr37/46), which plays a critical role in
translational mRNA complex assembly and found that PF-04691502 (500 nM) inhibited
expression of this protein at all time points; p4EBP-1 expression was markedly attenuated
at 24 and 48 h and completely inhibited at 72 h. A single treatment with PF-04691502
not only demonstrated sustained inhibition for the 24 h period in QGP-1 and BON cells
(Figure 2B), but also attenuated pAkt, pS6 and p4EBP-1 at 24 h in NT-3 cells (data not
shown). Moreover, these results demonstrate that PF-04691502 can effectively inhibit
PI3K/mTOR pathway components in both QGP-1 and BON cells for at least 72 h.
To determine the effect of PF-04691502 on GEP-NET cell proliferation, we treated
QGP-1 and BON cells with concentrations ranging from 100 to 10,000 nM for 120 h. The
percentage of cell inhibition was plotted against the concentration of PF-04691502 on a
logarithmic scale, and a standard curve was fitted to calculate the absolute IC-50 values. A
dose-dependent increase in percentage inhibition of cellular proliferation was observed
in both QGP-1 and BON cells (Figure 3A,B). The absolute IC-50 value, defined as 50%
inhibition compared to control, ranges from 168 nM for QGP-1 cells to 127.8 nM for
BON cells.




Figure 3. Analysis of QGP-1 and BON cells’ proliferation and cell survival after PF-04691502 treat-
ment. (A) QGP-1 and (B) BON cells were seeded in 96-well plates at 5000 cells/100 µL density (n = 
6 per group) and treated with PF-04691502 from 100 to 10,000 nM for 72, 96, and 120 h. Cell prolif-
eration was analyzed with SRB assay as described. Percentage inhibition of proliferation was plot-
ted against concentrations of PF-04691502 on a logarithmic scale. Absolute IC-50 was denoted by a 
dashed line and labeled, respectively. (C) QGP-1 and BON cells were seeded in a 96-well plate at 
200 cells/100 µL density (n = 6 per group) and treated with PF-04691502 from 25 to 500 nM. Cells 
were fixed and stained according to SRB protocol 14 d later. *, p < 0.01 versus control colorimetric 
cell survival by one-way ANOVA analysis. 
3.3. Cellular Profiling of PF-04691502 in Patient-Derived Tumor Spheroid Model 
Developing new preclinical models for GEP-NET is a well-known challenge, as slow 
growth and genetic stability limit the availability of NET cell lines, PDX and metastatic 
models [43]. We developed and evaluated 3D patient-derived NET spheroids to perform 
rapid and reliable evaluation of therapeutics in vitro. GEP-NET tumor samples M1893 
primary (pT3N2Mx, well-differentiated small intestinal NET) and M3210 primary 
(pT3N2M1a, well-differentiated small intestinal NET), with their respective lymph node 
(LN) metastasis, were established and cultured as tumor spheroids (Figure 4A). The neu-
roendocrine origin of the tumor spheroids was confirmed by immunoblotting analysis of 
neuroendocrine biomarkers: chromogranin A (CgA), somatostatin receptor 2 (SSTR2), 
and synaptophysin (SYP) (Figure 4B). After confirming that these patient-derived sphe-
roids were indeed neuroendocrine in origin, we treated the spheroids with PF-04691502 
(500 nM) for 24 h and determined expression of pAkt, pS6, and p4EBP-1. Similar to GEP-
NET cell lines, we observed the inhibition of pAkt, pS6, and p4EBP-1 expression in sphe-
roid samples at 24 h. In addition to the inhibition of the PI3K/Akt pathway, we also ob-
served inhibition of cyclin D1 after PF-04691502 treatment for 24 h. The CCK-8 viability 
assay, performed using two distinct patient-derived spheroid samples, showed a signifi-
cant 40% decrease in absorbance at 450 nm and thus proportional decrease in proliferation 
for both patient-derived spheroid samples (Figure 4D). These results demonstrate both 
the validity of our NET spheroid model as a reproducible tool for the evaluation of novel 
therapeutics and the anti-proliferative effect of PF-04691502 on GEP-NETs. 
Figure 3. Analysis of QGP-1 and BON cells’ proliferation and cell survival after PF-04691502 treat-
t. (A) QGP-1 and (B) BON cells w re se ed in 96-well plates at 5000 cells/100 µL density
(n = 6 per group) and treated with PF-04691502 from 100 to 10,000 nM for 72, 96, and 120 h. Cell
p oliferation w s analyzed with SRB assay as d scribed. Perc ntage inhibition of proliferation was
plotted against concentrations of PF-04691502 on a logarithmic scale. Absolute IC-50 was denoted by
a dashed line and labeled, respectively. (C) QGP-1 and BON cells were seeded in a 96-well plate at
200 cells/100 µL density (n = 6 per group) and treated with PF-04691502 from 25 to 500 nM. Cells
were fixed and stained according to SRB protocol 14 d later. *, p < 0.01 versus control colorimetric cell
survival by one-way ANOVA analysis.
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Next, we evaluated the effect of PF-04691502 on QGP-1 and BON cell survival. Cells
were treated with PF-04691502 (from 25 to 500 nM) and cell survival was quantified as
previously described. We noted a statistically significant decrease in cell survival at dosages
of 250 and 500 nM for both QGP-1 and BON cells (Figure 3C). These results demonstrate
significant antiproliferative activity of PF-04691502 in GEP-NET cell lines, particularly at a
dosage of 500 nM.
3.3. Cellular Profiling of PF-04691502 in Patient-Derived Tumor Spheroid Model
Developing new preclinical models for GEP-NET is a well-known challenge, as slow
growth and genetic stability limit the availability of NET cell lines, PDX and metastatic
models [43]. We developed and evaluated 3D patient-derived NET spheroids to perform
rapid and reliable evaluation of therapeutics in vitro. GEP-NET tumor samples M1893 pri-
mary (pT3N2Mx, well-differentiated small intestinal NET) and M3210 primary (pT3N2M1a,
well-differentiated small intestinal NET), with their respective lymph node (LN) metastasis,
were established and cultured as tumor spheroids (Figure 4A). The neuroendocrine origin
of the tumor spheroids was confirmed by immunoblotting analysis of neuroendocrine
biomarkers: chromogranin A (CgA), somatostatin receptor 2 (SSTR2), and synaptophysin
(SYP) (Figure 4B). After confirming that these patient-derived spheroids were indeed
neuroendocrine in origin, we treated the spheroids with PF-04691502 (500 nM) for 24 h
and determined expression of pAkt, pS6, and p4EBP-1. Similar to GEP-NET cell lines,
we observed the inhibition of pAkt, pS6, and p4EBP-1 expression in spheroid samples at
24 h. In addition to the inhibition of the PI3K/Akt pathway, we also observed inhibition
of cyclin D1 after PF-04691502 treatment for 24 h. The CCK-8 viability assay, performed
using two distinct patient-derived spheroid samples, showed a significant 40% decrease
in absorbance at 450 nm and thus proportional decrease in proliferation for both patient-
derived spheroid samples (Figure 4D). These results demonstrate both the validity of our
NET spheroid model as a reproducible tool for the evaluation of novel therapeutics and
the anti-proliferative effect of PF-04691502 on GEP-NETs.
3.4. Enhanced Radiosensitization of GEP-NET Cells via Schedule Dependent
PF-04691502 Treatment
Radiotherapy, namely PRRT, has emerged as the next-generation treatment for GEP-
NET patients [44,45]. Here, we tested the hypothesis that combination of a PI3K/mTOR
inhibitor with radiotherapy may enhance therapeutic effects in GEP-NETs. Radiotherapy
alone resulted in a dose-dependent increase in cleaved PARP expression, a marker of
apoptosis, in both QGP-1 and BON cells (Figure 5A). Notably, cleaved PARP expression
was detected at least 48 h after radiation in QGP-1 cells and 72 h after radiation in BON
cells, suggesting delayed radiation-induced apoptosis in GEP-NET cells. Therefore, we
hypothesized that NET cells are most sensitive to PI3K/mTOR inhibition after radiotherapy.
Next, QGP-1 and BON cells were irradiated (2 Gy) and then treated with PF-04691502
(500 or 1000 nM) for 24 h at 48, 72 or 96 h after radiation. We observed a significant in-
crease in cleaved PARP expression in cells treated with a combination of radiation and
PF-04691502 at 48 and 72 h post-radiation in QGP-1 cells and 96 h post radiation in BON
cells (Figure 5B). In contrast, increased cleaved PARP expression was not noted in cells
treated with 4 Gy radiation, immediately followed by PF-04691502 (500 nM or 1000 nM)
treatment for 24 h (Figure S3). Further DNA fragmentation ELISA immunoassay analysis
showed increased histone biotin and DNA peroxidase presence, markers of DNA frag-
mentation and apoptosis, in cells treated with a combination of radiotherapy (2 Gy) and
24 h treatment of PF-04691502 (500 nM) at 96 h after radiation. We observed a statistically
significant increase in DNA fragmentation in the 4 and 2 Gy subgroups for QGP-1 and
BON cells, respectively (Figure 5C). Our findings suggest that delayed treatment with a
PI3K/mTOR inhibitor after radiotherapy can result in increasing cytotoxic effects compared
to either drug or radiotherapy alone. Most importantly, our data demonstrate a schedule
dependence of apoptosis induction after radiation and PI3K/mTOR inhibition in GEP-NET
cells. Therefore, our results suggest the use of a PI3K/mTOR inhibitor in combination with
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radiotherapy in a delayed fashion as a possible treatment strategy to prevent disease pro-
gression and to promote disease regression in NET patients, as proposed in the schematic
diagram (Figure 5D).




Figure 4. Patient-derived NET tumor spheroids treatment with PF-04691502. (A) Photographs of 
tumor spheroids in low-attachment plates. GEP-NET patient tumor sample M3210 was a 
pT3N2M1a grade 2 tumor ileal neuroendocrine tumor, and tumor sample M1893 was a pT3N2Mx 
small intestinal neuroendocrine tumor. (B) GEP-NET tumor spheroids were plated in low-attach-
ment plates and 7 d later protein lysates were collected for GEP-NET origin confirmation by West-
ern blot. Mouse brain and mouse adrenal glands were used as positive controls for SYP and CgA, 
correspondingly. (C) GEP-NET tumor spheroids were seeded in low-attachment plates with equal 
density and treated with 500 nM PF-04691502 for 24 h. Protein lysates were collected to confirm 
PI3K/Akt pathway inhibition by pAkt (Ser473), pS6 (Ser235/236) and p4EBP-1 (Thr37/46) by im-
munoblotting. β-actin was used as a loading control. GAPDH was used as a loading control. (D) 
GEP-NET tumor spheroids were seeded in a 96-well clear round-bottom ultra-low attachment 
microplate at 10,000 cells / 1 mL density and treated 24 h later with 1000 nM PF-04691502. CCK-8 
reagent was added to each well 48 h later; CCK-8-induced colorimetric changes were measured by 
absorbance at 450 nM, which is directly proportional to the rate of cell proliferation, after 72 h. * 
denotes p-value < 0.01. 
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alone resulted in a dose-dependent increase in cleaved PARP expression, a marker of 
apoptosis, in both QGP-1 and BON cells (Figure 5A). Notably, cleaved PARP expression 
was detected at least 48 h after radiation in QGP-1 cells and 72 h after radiation in BON 
cells, suggesting delayed radiation-induced apoptosis in GEP-NET cells. Therefore, we 
hypothesized that NET cells are most sensitive to PI3K/mTOR inhibition after radiother-
apy. Next, QGP-1 and BON cells were irradiated (2 Gy) and then treated with PF-04691502 
(500 or 1000 nM) for 24 h at 48, 72 or 96 h after radiation. We observed a significant increase 
in cleaved PARP expression in cells treated with a combination of radiation and PF-
04691502 at 48 and 72 h post-radiation in QGP-1 cells and 96 h post radiation in BON cells 
(Figure 5B). In contrast, increased cleaved PARP expression was not noted in cells treated 
with 4 Gy radiation, immediately followed by PF-04691502 (500 nM or 1000 nM) treatment 
Figure 4. Patient-derived NET tumor spheroids treatment with PF-04691502. (A) Photographs of tumor spheroids in
low-attachment plates. GEP-NET patient tumor sample M3210 was a pT3N2M1a grade 2 tumor ileal neuroendocrine tumor,
and tumor sample M1893 was a pT3N2Mx small intestinal neuroendocrine tumor. (B) GEP-NET tumor spheroids were
plated in low-attachment plates and 7 d later protein lysates were collected for GEP-NET origin confirmation by Western blot.
Mouse brain and mouse adrenal glands were used as positive controls for SYP and CgA, correspondingly. (C) GEP-NET
tumor spheroids were seeded in low-attachment plates with equal density and treated with 500 nM PF-04691502 for 24 h.
Protein lysates were collected to confirm PI3K/Akt pathway inhibition by pAkt (Ser473), pS6 (Ser235/236) and p4EBP-1
(Thr37/46) by imm noblotting. β-actin was used as a loadi g control. GAPDH was sed as a loading control. (D) GEP-NET
tumor spheroids were seeded in a 96-well clear round-bottom ultra-low attachment microplate at 10,000 cells/1 mL density
and treated 24 h later with 1000 nM PF-04691502. CCK-8 reagent was added to each well 48 h later; CCK-8-induced
colorimetric changes were measured by absorbance at 450 nM, which is directly proportional to the rate of cell proliferation,
after 72 h. * denotes p-value < 0.01.
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Figure 5. Radiotherapy and schedule-dependent PF-04691502 therapy in NET cells. (A) QGP-1 (top) 
and BON (bottom) cells were seeded in a 6-well plate at 800,000 cells/2 mL density. Cells were then 
exposed to either control (0 Gy), 2, 4, or 8 Gy X-ray radiation. Protein lysates were collected at 24, 
48, 72, and 96 h after radiation exposure and analyzed for cleaved-PARP expression by immunob-
lotting. β-actin was used as a loading control. (B) QGP-1 (top) and BON (bottom) cells were seeded 
in 6-well plate at 800,000 cells/2 mL density and exposed to 2 Gy X-ray radiation. Cells were incu-
bated for either 48, 72, or 96 h and then treated with PF-04691502 at 500 or 1000 nM for 24 h prior to 
protein lysates collection. Cleaved-PARP expression was determined by immunoblotting analysis. 
β-actin was used as a loading control. (C) QGP-1 and BON cells were seeded at 1000 cells/100 uL 
density in 96-well plates and exposed to 2 Gy X-ray radiation. Cells were incubated for 96 h and 
treated with PF-04691502 at 500 nM for 24 h prior to lysate collection and analysis as described. 
DNA fragmentation and cell death induced proportional colorimetric change, which was measured 
by absorbance at 405 nm (n = 6). * denotes p-value < 0.01. (D) Proposed schematic diagram for sched-
ule-dependent PI3K/mTOR inhibition after radiotherapy in NET patients. 
Our study explored the therapeutic potential of inhibiting the PI3K/mTOR/Akt path-
way, which plays a crucial role in NET pathogenesis [14,49]. The mTOR pathway, one of 
Figure 5. Radiotherapy and schedule-dependent PF-04691502 therapy in NET cells. (A) QGP-1 (top) and BON (bottom)
cells were seeded in a 6-well plate at 800,000 cells/2 mL density. Cells were then exposed to either control (0 Gy), 2, 4,
or 8 Gy X-ray radiation. Protein lysates were collected at 24, 48, 72, and 96 h after radiation exposure and analyzed for
cleaved-PARP expression by immunoblotting. β-actin was used as a loading control. (B) QGP-1 (top) and BON (bottom)
cells were seeded in 6-well pl e at 800,000 cells/2 mL density and exposed to 2 Gy X-ray r diation. Cells were incubated
for either 48, 72, or 96 h and then treated with PF-04691502 at 500 or 1000 nM for 24 h prior to pr tein lysates c llection.
Cleaved-PARP expression was determined by immunoblotting analysis. β-actin was used as a l ading control. (C) QGP-1
and BON cells were seeded at 1000 cells/100 uL density in 96-well plates and exposed to 2 Gy X-ray radiation. Cells were
incubated for 96 h and treated with PF-04691502 at 500 nM for 24 h prior to lysate collection and analysis as described. DNA
fragmentation and cell death induced proportional colorimetric change, which was measured by absorbance at 405 nm
(n = 6). * denotes p-value < 0.01. (D) Proposed schematic diagram for schedule-dependent PI3K/mTOR inhibition after
radiotherapy in NET patients.
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4. Discussion
GEP-NET is a subset of aggressive gastrointestinal NETs, often diagnosed as advanced
disease with poor prognosis [3]. Improved treatment options are needed, as a third of
GEP-NET patients do not respond to current regimens [2,3,18]. Radiotherapy and mTOR
inhibition are two promising therapies that have improved treatment outcomes, such as
progression-free survival [4,5,16,19,22]. PRRT is a form of targeted radiotherapy, coupled
with either an alpha-emitter or a beta-emitter and a somatostatin analog to induce DNA
damage in targeted GEP-NETs overexpressing somatostatin receptors [4,9]. It has become a
prevalent treatment among patients with inoperable and metastatic somatostatin receptor-
positive GEP-NETs [4,9,46], with clear progression-free survival benefit and improved
quality of life among patients [47,48]. Despite the fact that the initial PRRT treatment
resulted in stable disease in up to 80% of patients, all patients eventually progressed over
time [4,5,9,47,49].
Our study explored the therapeutic potential of inhibiting the PI3K/mTOR/Akt
pathway, which plays a crucial role in NET pathogenesis [14,49]. The mTOR pathway, one
of the most significant targets in modern cancer treatment [14,50], is triggered by growth
factors and is responsible for cell survival, proliferation and angiogenesis [14]. There are
multiple downstream targets of the mTOR pathway, such as the ribosomal protein S6
kinase 1 (S6K1) and eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1
(4E-BP1) [51]. The S6 protein is a key regulator of 40S ribosome subunit biogenesis and
4E-BP1 has a critical role in translational mRNA complex assembly [50,52,53]. Together,
these two proteins are phosphorylated by mTORC1 to promote translation and protein
synthesis [50,53]. Clinically, inhibition of S6 and 4E-BP1 phosphorylation are two important
therapeutic targets for multiple malignancies [51,52,54,55]. Everolimus, a rapamycin analog
and potent mTORC1 inhibitor [56], was used to treat GEP-NETs in the RADIANT clinical
trial series [15–20]. Though everolimus showed improved progression-free survival in the
short term, only 10% of patients had disease regression [15]. This could be secondary to the
negative feedback loop of the mTORC2/Akt pathway [57]. The protein S6K inhibits the
mTORC2 complex and Akt, which forms the negative feedback loop. Therefore, inhibition
of S6K by mTORC1 inhibitor could result in Akt pathway activation through mTORC2
signaling, thus providing an escape mechanism and incomplete inhibition of downstream
effectors [57]. Therefore, a new class of PI3K/mTOR dual inhibitors was developed to
provide complete inhibition of the mTOR/Akt pathway [24,54].
In contrast to everolimus, the PI3K/mTOR dual inhibitors, PF-04691503 and PKI-402,
tested in this study, primarily inhibit PI3K and Akt phosphorylation, an upstream mediator
of both mTORC1 and mTORC2 complexes [24]. Inhibition of Akt results in dual inhibition
of the mTORC1 and mTORC2, thus preventing the escape negative feedback loop [54].
Our study identified abundant expression of pAkt in the cytoplasm of GEP-NET, which
is the primary target of the PI3K/mTOR dual inhibitor (see Figure 1). We also demon-
strated significant and prolonged attenuation of pAkt, pS6, and p4EBP-1 expression and
antiproliferative properties of the PI3K/mTOR dual inhibitors in vitro. This is consistent
with previous studies where PI3K/mTOR dual inhibitors showed antineoplastic properties
in various cancer cell lines [58–62]. Despite the abundant supporting evidence for their
antineoplastic properties, multiple clinical trials of PI3K/mTOR dual inhibitors reported
unacceptable toxicity, resulting in the early termination of trials, including one phase II
study in pNET [26,28,63,64]. Thus, it has a limited role in cancer treatment as a single
agent [24,25,58]. However, its role as a radiosensitizer has not been previously studied.
Radiotherapy, which utilizes ionized radiation, directly or indirectly damages cellular
DNA in cells undergoing rapid division and activates cell survival pathways [65,66]. The
ionizing energy can break the double helix DNA structure, which subsequently results in
programmed cell death if not repaired successfully, or induce single strand DNA break,
which leads to prolonged cell autophagy or cell cycle arrest [66]. When cells sustain
DNA damage, the non-homologous end joining (NHEJ) or homologous recombination
(HR) repair pathways become activated and phosphorylate ATR, ATM and DNA-PK to
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promote cell survival [65,66]. The PI3K/mTOR/Akt pathway responds to ATM and DNA-
PK phosphorylation through AMPK signaling, and triggers its downstream effectors to
promote survival, proliferation and angiogenesis, as described previously [65]. This forms
the basis for our hypothesis that PI3K/mTOR dual inhibitor could enhance the cytotoxic
effect of radiotherapy.
Our laboratory recently showed that Akt1 expression plays a major role in the ra-
diosensitivity of triple negative breast cancer [38]. Therefore, we hypothesized that com-
bining radiotherapy and PI3K/mTOR dual inhibitor could prevent the cell survival re-
sponse to DNA damage from radiation therapy, thus achieving synergistic cytotoxic effect
through a multimodal approach. We used PI3K/mTOR dual inhibitors, which prevent
re-activation of mTOR through negative feedback, and combined it with radiotherapy
to induce synergistic apoptosis in GEP-NET cell lines. In addition to the radiosensitiza-
tion by PI3K/mTOR inhibitions, our study identified a schedule-dependent induction of
apoptosis. Pre-radiation and simultaneous treatment with PF-04691502 did not increase
apoptosis, while PF-04691502 administered post-radiation produced a synergistic induction
of apoptosis compared to either PF-4691502 or radiation alone. Moreover, cells did not
undergo apoptosis immediately after radiation. In contrast, there was a delayed apoptotic
response at 48 h and at longer time points. Prior preclinical studies have also noted a
schedule-dependent radiosensitization using sorafenib and erlotinib [67,68]. One study
suggested that this variation could be due to PI3K signal transduction and its regulatory
effects [68]. Schedule-dependent PI3K/mTOR inhibition has a potential to reduce the fre-
quency of side effects observed after PI3K/mTOR pathway inhibition by reducing number
of administered doses required to achieve cytotoxic effects in cancer cells.
In summary, we demonstrate that PF-06491502 is a long-acting PI3K/mTOR inhibitor
with antineoplastic activity, which can also potentiate radiotherapy when administered in
a schedule-dependent fashion. Our findings suggest that PI3K/mTOR inhibitors should
be administered in the short term after radiation therapy to potentiate radiotherapy and
to possibly improve clinical outcomes in GEP-NET patients. Short-term exposure of
PI3K/mTOR inhibitor administration in this setting could prevent toxicity of inhibitors
associated with long-term treatment.
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